With myopia rates climbing steeply in Western countries, the absence of proven non-pharmacological interventions for non-Asian children has left clinicians with limited options. A rigorously designed US trial now changes that calculus, demonstrating that a specific optical lens design can dramatically slow eye elongation in American children — a population previously underrepresented in myopia control research.
This double-masked randomized clinical trial enrolled 159 children aged 6–12 years across nine US sites, all presenting with mild-to-moderate myopia (spherical equivalent refraction of −0.75 to −4.50 diopters). Participants were assigned equally to either highly aspherical lenslet (HAL) spectacles or conventional single-vision lenses (SVL). Over 24 months, those wearing HAL lenses progressed only −0.25 diopters compared with −0.90 diopters in the SVL group — a 71% relative reduction in myopic progression. Axial length elongation, the structural measure most directly linked to long-term ocular pathology risk, was similarly attenuated in the HAL group. Retention was strong, with 84.9% completing the full follow-up period.
The significance of these findings extends well beyond optics. Axial elongation beyond roughly 26mm is associated with substantially elevated lifetime risk of retinal detachment, glaucoma, and macular degeneration — conditions that compound silently over decades. HAL lenses work by creating a defocus shell across the peripheral retina, theoretically signaling the eye to decelerate growth. Prior evidence for this mechanism came predominantly from East Asian cohorts, where myopia genetics, diet, and outdoor exposure patterns differ from Western populations. This trial's US-specific design addresses a critical generalizability gap. Limitations include a 24-month horizon (longer follow-up would clarify whether the effect persists or attenuates), a relatively small sample, and the exclusion of children with prior myopia interventions. Still, as a double-masked RCT published in a top-tier journal, this represents a meaningful advance — potentially paradigm-shifting for US pediatric eye care where spectacle-based myopia control has lacked FDA-context evidence.